Overview

Pharmacokinetics of Ultra-Rapid-Acting Insulin Lispro (URAL) in Type 1 Diabetes Mellitus

Status:
Withdrawn
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
To compare the early pharmacokinetic exposure of URAL and insulin lispro (ILisp).
Phase:
Phase 1
Details
Lead Sponsor:
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Perosphere, Inc.
Collaborator:
Profil Institut für Stoffwechselforschung GmbH
Treatments:
Insulin
Insulin Lispro
Insulin, Globin Zinc
Insulin, Short-Acting